OBJECTIVES: To assess the postoperative incidence of major complications in high-risk patients following video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer compared with their lower risk counterparts.
INTRODUCTION
Early-stage lung cancer, which benefits from radical surgery, is often diagnosed in patients with multiple comorbidities and in an increasingly older population. Comorbidities have an intrinsic impact on each patient's treatment and its efficacy, especially when we refer to a surgical treatment. It has been shown that a minimally invasive surgical approach for lung cancer [video-assisted thoracoscopic surgery (VATS) lobectomy] reduces postoperative morbidity and mortality, shortens the hospital stay and provides at least the same long-term prognosis compared with thoracotomy. For this reason, it is currently the recommended surgical approach for early-stage lung cancer surgical patients [1] . The decreased surgical trauma associated with VATS is particularly beneficial to patients considered at high risk for surgery. In this regard, several authors have demonstrated that patients with a compromised respiratory function and candidates for pulmonary lobectomy for cancer experienced a much more favourable outcome after VATS compared with thoracotomy [2] [3] [4] [5] . However, in this era of patient-shared decision-making, a more accurate knowledge of the actual risk of major morbidity following VATS lobectomy in high-risk patients is fundamental, since this might influence the treatment choice.
Therefore, the objective of this study was to assess the incidence of major complications following VATS lobectomy in high-risk patients compared with case-matched lower risk counterparts.
PATIENTS AND METHODS
We performed a retrospective analysis on prospectively collected data of 348 consecutive patients who underwent a VATS lobectomy for lung cancer (August 2012-September 2014). The study was reviewed and approved by the local Institutional Review Board. All patients with a diagnosis of lung cancer were discussed by a multidisciplinary team of specialists (MDT) (chest physicians, medical oncologists, clinical oncologists, radiologists and thoracic surgeons) for indication to potential surgical treatment for lung cancer, on the basis of imaging [X-rays, computed tomography (CT) scans, positron emission tomography scan, magnetic resonance imaging] and invasive procedures for diagnosis and staging (CT-guided biopsy, EBUS, EUS, thoracoscopic biopsies). Patients with a known cardiac history were preoperatively assessed by a cardiac specialist in order to perform specific cardiological examinations (electrocardiogram, echocardiography etc.) to be deemed fit for surgery. Such patients and those with relevant comorbidities and/or with spirometry indicating predicted postoperative forced expiratory volume in 1 s (ppoFEV1) or predicted postoperative carbon monoxide lung diffusion capacity (ppoDLCO) <60% were further investigated with a cardiopulmonary function test [6] . According to the existing American College of Chest Physicians (ACCP) guidelines [6] , patients were considered inoperable if they had a ppoFEV1 and ppoDLCO <30%, in association with a VO 2 max <10 ml/kg/min.
Board-qualified thoracic surgeons operated all patients through a 2-to 3-port VATS access. All patients were extubated in the operation theatre and transferred to a high dependency unit for the first night after surgery, from which they were moved to a dedicated thoracic ward bed the next day.
All patients were managed according to standardized pathways of care, including venous thromboembolism prophylaxis, chest physiotherapy and rehabilitation. Pain control was achieved with a combination of paravertebral and intravenous patient-controlled analgesia to maintain the numeric pain score consistently below 4 in a visual analogical scale.
Design of the study
For the purpose of this study, all the patients were arbitrarily classified into a high-risk or a low-risk group. The high-risk group consisted of patients with one or more of the following clinical characteristics: age >75 years, FEV1 <50%, DLCO <50% and history of CAD. Those patients without any of these characteristics were considered in the low-risk group of patients.
All patients' comorbidities were evaluated by the Charlson's Comorbidity Index (CCI) as it is considered the gold standard to assess comorbid risk in clinical research [7] [8] [9] .
The following in-hospital or 30-day cardiopulmonary complications were included and defined according to the STS-ESTS joint definitions [10] : respiratory failure, atelectasis requiring bronchoscopy, pneumonia, acute distress respiratory syndrome, pulmonary embolism, pulmonary oedema, atrial arrhythmia, myocardial infarction, cerebrovascular complications, acute renal failure.
The severity of complications was in both groups graded by means of the Thoracic Morbidity and Mortality (TM&M) scoring system [11] [12] [13] (Table 1) . Major complications were defined as such if the TM&M score was greater than 2.
Statistical method and variables
To minimize the influence of other confounders on outcome, we used a propensity score analysis [14, 15] to match high-risk patients with lower risk counterparts. The following variables were used to construct the propensity score: gender, side of operation, body mass index, American Society of Anaesthesiologists score, Eastern Cooperative Oncology Group performance score, CCI, number of functioning segments resected. The two matched groups were then compared in terms of baseline characteristics and incidence of postoperative major cardiopulmonary complications. The standardized difference (effect size) was used to assess the magnitude in differences of preoperative variables between the two groups. According to the Cohen classification, an effect size between −0.2 and 0.2 indicates a small difference [16] . The standardized difference appears more appropriate than the P value to establish whether an adequate balance was achieved in matching, as it is less sensitive to sample size [17] . Postoperative categorical outcomes (complications and mortality) were compared by means of the McNemar test, numeric outcome ( postoperative stay) was compared by means of the Wilcoxon signed-rank sum test. A P value of 0.05 was accepted as significant. The statistical tests were performed on the statistical software Stata 12.0 (Stata Corp., College Station, TX, USA).
RESULTS
The cumulative cardiopulmonary and mortality rates in all patients were 14% (47 patients) and 1.8% (6 patients), respectively. The average hospital stay was 6.5 (range 1-96 days). The high-risk group consisted of 141 patients (age >75 years: 84 patients; FEV1 <50: 14 patients; DLCO <50: 25 patients; history of CAD: 37 patients). Table 2 describes the baseline characteristics of all patients included in the study.
Before matching, the comparison between high-risk and low-risk patients showed that the former had a higher cardiopulmonary morbidity rate (21 vs 9%, P = 0.0011) and similar mortality rate (2 vs 1.5%, P = 0.63).
With the exception of a lower performance status in the higher risk group, the propensity score yielded two groups of 135 patients each (high risk vs low risk), well balanced for several baseline characteristics (Table 3) .
Compared with their low-risk counterparts, the high-risk patients had a higher incidence of total cardiopulmonary complications (28 cases, 21% vs 14 cases, 10%; P < 0.0001) and major cardiopulmonary complications (12 cases, 9% vs 3 cases, 2%; P = 0.019). Also, the postoperative stay was 3 days longer for the high-risk patients (8.6 vs 5.5 days, P = 0.0031). Thirty-day or in-hospital mortality rates were not different between the two groups (2 cases, 1.5% vs 3 cases, 2.2%, P = 0.93).
DISCUSSION
Background and rationale for the study Video-assisted thoracoscopic surgery (VATS) has become the recommended approach for anatomical lung resection in early-stage lung cancer patients [18] . Several studies have shown the superiority of VATS lobectomy compared with lobectomy by thoracotomy since it was associated to less complications, a faster recovery and similar oncological results [1, [19] [20] [21] . These benefits are particularly important in those patients known to be at higher surgical risk, such as the elderly, and patients with compromised pulmonary physiology and with comorbidities. Especially in this era of patientshared decision-making, it is fundamental for the thoracic surgeon to gain more knowledge to be passed on to a high-risk patient while discussing the risks of undergoing a VATS lobectomy, particularly in the light of other available treatments. In fact, we believe that there is a gap of knowledge in terms of quantification of potential morbidity of high-risk patients submitted to a minimally invasive surgical approach for lung cancer. Therefore, with this study, we aimed to assess the impact of VATS lobectomy on patients considered at high risk for surgery by quantifying the postoperative incidence of total major complications, cardiopulmonary complications, postoperative length of stay (LOS) and mortality, and then comparing them with their low-risk counterparts.
Main findings
The analysis performed on our cohort of patients demonstrated that the high-risk subset of patients had a 50% increased risk of developing total major complications and a 4-fold higher incidence of cardiopulmonary complications compared with the low-risk group. Moreover, the LOS for the high-risk patients was 3 days longer. The cardiopulmonary morbidity rate in the high-risk patients was only 9% and the mortality rates between the two groups were similar. These results are important since they quantify the risk that high-risk patients encounter when undergoing a VATS lobectomy for lung cancer.
Our study supports the indication that if a high-risk patient has to undergo surgery for lung cancer, VATS is preferable to thoracotomy [3, 20] , due to the above-mentioned intrinsic benefits of minimally invasive lobectomy, but points out that high-risk patients have a non-negligible surgical risk compared with the normal population.
Supposedly, the explanation of this still increased risk should be searched in the physiological and comorbid set intrinsic in the definition of high-risk patients. As mentioned above, we arbitrarily decided on the parameters to define our high-risk category of patients, being them proved independent factors associated with overall survival (advanced age, FEV1 <50%, DLCO <50% and CAD) and because, to date, there is no homogeneous consensus among lung cancer surgeons on the definition of 'high-risk' VATS lobectomy patients [22, 23] . Studies performed in large cohorts of lobectomy patients, investigating postoperative morbidity in patients with low DLCO [5] , in patients considered to be at high risk for lobectomy [21] or in elderly patients [22] , have shown higher cardiopulmonary complication rates when compared with our VATS cohort of high-risk patients, indirectly reflecting the benefits of VATS lobectomy.
On evaluating an adequate therapeutic strategy (MDT) for the high-risk patients, it is necessary to consider that they may experience greater postoperative complications, but should not be excluded from the possibility of undergoing a VATS lobectomy, if feasible for this reason, since surgery still remains the gold standard for operable lung cancer. A further level of investigation is hence recommended (i.e. cardiopulmonary exercise test, quantitative CT scan, ventilation/perfusion scintigraphy etc.) before excluding the high-risk patients from surgery, also bearing in mind that this kind of investigation may still be cost beneficial.
Furthermore, the option of offering high-risk patients a VATS sublobar resection whenever feasible may be a valid alternative to a VATS lobectomy and should not be discarded, as evidenced in a recent multicentre randomized trial [23] .
However, apart from the quantification of postoperative morbidity and in-hospital mortality in high-risk patients undergoing VATS lobectomy, there are other crucial factors that should be taken into account by the patient in order to express a judgement on operability (shared decision-making), such as the residual quality of life (QoL) and the long-term survival. As patients focus more on their risk of being mentally impaired or being unable to resume their daily lifestyle, rather than the surgery-related specific morbidity, one should evaluate the evidence of an acceptable QoL in patients with comorbidities during the surgical decision-making with the patient [24, 25] .
Limitations
We have to acknowledge certain limitations of our study.
Firstly, this is a retrospective study with inherent selection bias. We have used a propensity score case-matching analysis to minimize this bias, as this technique is regarded as the most reliable method for a balanced comparison in a non-randomized setting. Propensity score analysis yielded two well-balanced groups for several variables.
For the purpose of this study, we included only pulmonary lobectomies. Results should not be generalized to sublobar resections.
As mentioned above, the definition of high-risk patients was arbitrarily chosen based on the best available evidence and clinical experience. The use of different factors or different thresholds may have yielded different results.
Cardiopulmonary exercise test was not available in all patients, and parameters such as VO 2max were therefore not used to classify high-risk patients in this study.
CLINICAL IMPLICATIONS AND CONCLUSIONS
We were able to quantify the risk that high-risk patients face when subjected to a minimally invasive approach for lung cancer compared with their low-risk counterparts. The incidence of major complications after VATS lobectomy in high-risk patients is low but not negligible.
This information can be used as a decision aid tool during the multidisciplinary team discussion and during patient counselling, in order to decide the best therapeutic strategy.
